A Study of PHN-012 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Pheon Therapeutics
Astellas Pharma Inc
Montefiore Medical Center
Iambic Therapeutics, Inc
Revolution Medicines, Inc.
Coherus Oncology, Inc.
Conjupro Biotherapeutics, Inc.
Alterome Therapeutics, Inc.
Amgen
Aptamer Sciences, Inc.
Erasca, Inc.
GlaxoSmithKline
Rondo Therapeutics
RasCal Therapeutics, Inc.
Vividion Therapeutics, Inc.
Centre Oscar Lambret
Eisai Inc.
Cartography Biosciences
ViroMissile, Inc.
Replimune Inc.
Pfizer
AstraZeneca
Tizona Therapeutics, Inc
SEED Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Angiex, Inc.
Pheon Therapeutics
Conjupro Biotherapeutics, Inc.
AgonOx, Inc.
GlaxoSmithKline
Novartis
Sairopa B.V.
Bristol-Myers Squibb
Degron Therapeutics Co.
Elevation Oncology
AstraZeneca
Coherus Oncology, Inc.
St. Jude Children's Research Hospital
Tesaro, Inc.
Turning Point Therapeutics, Inc.
HUYABIO International, LLC.
HUYABIO International, LLC.
National Institutes of Health Clinical Center (CC)
Chiome Bioscience Inc.
Pfizer
Sanofi
UNC Lineberger Comprehensive Cancer Center
Nurix Therapeutics, Inc.
Incyte Corporation